Efficacy of risedronate in Japanese male patients with primary osteoporosis

Internal Medicine

Volumn 47, Issue 8, 2008, Pages 717-723

  Majima, Takafumi ^a,c   Shimatsu, Akira ^a   Komatsu, Yasato ^b   Satoh, Noriko ^a   Fukao, Atsushi ^d   Ninomiya, Kiyoshi ^c   Matsumura, Tadashi ^c   Nakao, Kazuwa ^b  

^a Center for Endocrine and Metabolic Diseases   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c RAKUWAKAI OTOWA HOSPITAL   (Japan)

^d Ainogakuin College   (Japan)

Author keywords

Bone mineral density; Bone turnover markers; Male; Osteoporosis; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; RISEDRONIC ACID; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; DRUG DERIVATIVE; ETIDRONIC ACID; PEPTIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIETARY INTAKE; DRUG EFFICACY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC DISCOMFORT; FEMUR NECK; HUMAN; JAPAN; KINESIOTHERAPY; LUMBAR SPINE; MALE; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RADIUS; SCORING SYSTEM; TIME; BONE; DOSE RESPONSE; DRUG EFFECT; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PHOTON ABSORPTIOMETRY; PROSPECTIVE STUDY;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; PROSPECTIVE STUDIES;

EID: 44649185881     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0591     Document Type: Article

References (30)

1. Orimo H, Hashimoto T, Sakata K, Yoshimura. N, Suzuki T, Hosoi T. Trends in the incidence of hip fracture in Japan, 1987-1997: the third nationwide survey. J Bone Miner Metab 18: 126-131, 2000.
2. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13: 195-199, 2002.
3. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 16: 87-116, 1995.
4. Campion JM, Maricic MI. Osteoporosis in men. Am Fam Physician 67: 1521-1526, 2003.
5. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2: 285-289, 1992.
6. Fujiwara S, Kasagi F, Yamada M, Kodama K. Risk factors for hip fracture in a Japanese cohort. J Bone Miner Res 12: 998-1004, 1997.
7. Cooley H, Jones G. A population-based study of fracture incidence in southern Tasmania: lifetime fracture risk and evidence for geographic variations within the same country. Osteoporos Int 12: 124-130, 2001.
8. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman A. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4: 277-282, 1994.
9. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N EngI J Med 343: 604-610, 2000.
10. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11: 98-101, 2000.
11. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86: 5252-5255, 2001.
12. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24: 110-113, 2004.
13. Drake WM, Kendler DL, Rosen CJ, Orwoll ES. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Cho Endocrinol Metab 88: 5759-5765, 2003.
14. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226, 2003.
15. Iwamoto J, Takeda T, Sato Y. Prevention and treatment of corticosteroid-induced osteoporosis. Yonsei Med J 46: 456-463, 2005.
16. Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao, A, Morimoto T, Comers J, Nakao K. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab 24: 105-113, 2006.
17. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26: 427-431, 2006.
18. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind doseranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14: 225-234, 2003.
19. Orimo H, Hayashi Y, Fukunaga M, et al. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19: 331-337, 2001.
20. Matsumoto T. New guideline for the treatment of osteoporosis. Nippon Rinsho 62 (suppl 2): S387-S391, 2004 (in Japanese).
21. Hayashi Y. Clinical practice guidelines for diagnosis and treatment of osteoporosis. Nippon Rinsho 61: 245-251, 2003 (in Japanese).
22. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20: 433-439, 2004.
23. Takada J, Iba K, Imoto K, Yamashita T. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 25: 142-146, 2007.
24. Mashiba T, Mori S, Burr DB, Komatsubara. S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23: S36-S42, 2005.
25. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga A Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18: 1547-1553, 2003.
26. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10: 183-192, 1999.
27. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58: 288-298, 1995.
28. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8: 563-569, 1998.
29. Rosen CJ, Hochberg MC, Bormick SL, et al. Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 ing compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized doubleblind study. J Bone Miner Res 20: 141-151, 2005.
30. Kishimoto H, Fukunaga M, Kushida K, et al; Risedronate Phase III Research Group. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24: 405-413, 2006.